Cells treated for 24 h with bortezomib confirmed that Cbfb+/56MFbxo9−/− tumor cells were more sensitive to proteasome inhibition than Cbfb+/56MFbxo9+/+ tumor cells, with IC50 calculations of 10.03 nM and 11.76 nM, respectively. Here, CBFB is linked to neoplasm.